To the Editor.—
We read with great interest the recent article by Morhenn et al1 entitled "Use of Recombinant Interferon Gamma Administered Intramuscularly for the Treatment of Psoriasis." Their results are in good agreement with those we reported previously,2,3 showing that systemic treatment of psoriasis with recombinant interferon-gamma (rIFN-gamma) (1) leads to the expression of HLA-DR antigen on keratinocytes in psoriatic lesions in vivo, (2) nevertheless does not clear psoriatic lesions, and (3) may increase the serum triglycéride level. In fact, these findings were presented at the Dermatopharmacology Symposium, at Stanford (Calif) in 1985, the Fourth International Symposiumon Psoriasis, at Stanford (Calif) in 1986, and at the on Psoriasis, at Stanford (Calif) in 1986, and at the 45th annual meeting of the American Academy of Dermatology, at New Orleans in 1986.Morhenn et al1 injected rIFN-gamma intramuscularly and suggested that "intralesional administration of rIFN-gamma might prove advantageous."
Schulze H, Mahrle G. Recombinant Interferon Gamma in Psoriasis. Arch Dermatol. 1988;124(4):487–488. doi:10.1001/archderm.1988.01670040007003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: